Surgical securement (sealants, glues, hemostasis, etc.) applicable caseload in cardiovascular disease

See updated analysis in October 2014 report, “Worldwide Market for Surgical Sealants, Glues, and Wound Closure, 2013-2018”, Report #S192.

Cardiovascular disease is the leading cause of mortality in the United States with heart disease affecting 13 million people. Approximately 10% of these patients are estimated to be candidates who, as part of their primary treatment are also candidates for the most advanced technologies in surgical securement. Current uses of surgical securement technologies in cardiovascular disease are focused on coronary heart disease, myocardial infarction, end-stage congestive heart failure, dysfunctional heart valves, and peripheral vascular disease.

cardio-securement

Source: MedMarket Diligence, LLC; Report #S175.

 

Cardiovascular disease is a major (and growing) public health problem in developed countries, representing a major outlay of health care expenditures. It is the highest cause of death in the United States. Major multinational companies have targeted segments within this market and have promoted innovative solutions to both invasive and minimally invasive treatment of these disease states. These companies have also invested heavily in new procedures such as radiofrequency and transmyocardial laser revascularization, and biventricular pacing devices. In the future, adjunctive closure and securement products offer the potential to treat cardiovascular disease with products that aid the tissue repair process, encouraging faster recovery of surgical procedure site and donor sites.

The increasingly aging population, together with unhealthy dietary habits and a sedentary existence, are contributing to an expanded cardiovascular disease pool. The success of measures to prevent mortality from other diseases also increases this effect. In addition, rising gross domestic product (GDP) is driving increasing surgical procedure uptake in developing countries. Therefore, a huge opportunity exists for new sealant, hemostasis and closure solutions in cardiovascular surgery once new procedure-driven technical hurdles are overcome.


MedMarket Diligence, LLC; Report #S175: “Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2009-2013.” Details.

1 thought on “Surgical securement (sealants, glues, hemostasis, etc.) applicable caseload in cardiovascular disease”

  1. I have been suffering from Congestive Heart Failure for the last 16 years and as far as I knew there was no effective treatment. Trying to get doctors to listen to new treatments in the UK is very difficult. If at all possible I would like permission to re-print this article on my website at http://www.congestive-heart.com for the benefit of my readers.

    Best wishes – Mark

Leave a Reply